How Will The Point-Of-Care Molecular Diagnostics Market Globally Expand In 2023?
The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032
The Business Research Company’s point-of-care molecular diagnostics market report forecasts the point-of-care molecular diagnostics market size to grow to $4.98 Billion by 2027, with a CAGR (compound annual growth rate) of more than 12%.
Learn More On The Point-Of-Care Molecular Diagnostics Market Report 2023 – https://www.thebusinessresearchcompany.com/report/point-of-care-molecular-diagnostics-global-market-report
Point-Of-Care Molecular Diagnostics Market Size Forecast
The global point-of-care molecular diagnostics market is expected to grow from $2.8 billion in 2022 to $3.14 billion in 2023 at a compound annual growth rate (CAGR) of 12.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The point-of-care molecular diagnostics market size is expected to grow to $4.98 billion in 2027 at a CAGR of 12.2%.
North America held the largest point-of-care molecular diagnostics market share, and Asia-Pacific was the fastest-growing region in 2022.
Key Point-Of-Care Molecular Diagnostics Market Driver – Growth In The Increasing Occurrence Of Infectious And Respiratory Diseases
For instance, in May 2020, an annual Report on MCCD (Medical Certification of Cause of Death) 2020 shows that respiratory system diseases are the second most common cause of death, accounting for 10% of the total medically certified causes of death (88.7%). Furthermore, between 2019 and 2020, the number of deaths caused by respiratory disorders increased from 152,311 to 181,160. Therefore, the rapid occurrence of infectious and respiratory diseases and death will drive the point-of-care-molecular diagnostics market.
Request for A Sample Of The Global Point-Of-Care Molecular Diagnostics Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7046&type=smp
Key Point-Of-Care Molecular Diagnostics Market Trend – Technological Innovation
Major companies operating in the point-of-care molecular diagnostics market are focused on providing technologically advanced solutions to strengthen their market position. These companies are implementing next-generation point-of-care molecular diagnostics technologies solutions and related services, such as enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), and mass spectrometry (MS), situ hybridizations, spectral karyotyping imaging, DNA microarrays, and others to implement on POC devices with features of accelerating analysis times and lowering costs. For instance, in March 2020, Abbott Laboratories, a US-based medical device company, launched the molecular point-of-care test available for detecting new COVID-19 (COVID-19). According to the company, the device shows positive results in five minutes and negative in 13 minutes. This test will run on the ID NOW™ platform with isothermal nucleic acid amplification technology that generates molecular results in minutes.
Point-Of-Care Molecular Diagnostics Market Segment
1) By Product And Service: Assays And Kits, Instruments And Analyzers, Software And Services
2) By Technology: Reverse Transcription – Polymerase Chain Reaction (RT-PCR), In Situ Hybridization, Sequencing
3) By Application: Respiratory Diseases, Hospital Acquired Infections (HAIs), Cancer/Oncology, Hepatitis, Hematology
4) By End-User: Decentralized Labs, Hospitals, Home Care, Assisted Living Healthcare Facilities
Point-Of-Care Molecular Diagnostics Market Major Players and Strategies
Major players in the point-of-care molecular diagnostics market are Abbott Laboratories, F Hoffmann-La Roche Ltd., BioMérieux SA, Danaher Corporation, Quidel Corporation, Qiagen Gmbh, Biocartis NV, Nova Biomedical, Thermo Fisher Scientific, Dickinson and Company, Mesa Biotech Inc., OraSure Technologies Inc., Bio-Rad Laboratories Inc., Sysmex, Siemens Healthineers, Bayer HealthCare Pharmaceuticals LLC, Alere Inc., Lucira Health Inc., Cue Health, OpGen Inc., Binx Health Inc., Molbio Diagnostics Pct Ltd., Genomadix, Visby Medical, QuikPath PTE Ltd., QuantuMDx Group Ltd and Sekisui Medical Co Ltd.
In February 2021, Thermo Fisher Scientific, a US-based supplier of scientific instrumentation, reagents, consumables, and software services firm acquired Mesa Biotech for an undisclosed amount. With this acquisition, Thermo Fisher Scientific will expand into molecular diagnostics at the point-of-care by bringing much-needed diagnostics to market on a larger scale. Mesa Biotech is a US-based point-of-care molecular diagnostic company.
The Point-Of-Care Molecular Diagnostics Global Market Report 2023 covers regional data on point-of-care molecular diagnostics market size, point-of-care molecular diagnostics market trends and drivers, opportunities, strategies, and point-of-care molecular diagnostics market competitor analysis. The countries covered in the point-of-care molecular diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
Point-of-care (POC) molecular diagnostics refers to tests that detect the presence of specific nucleic acids in a clinical specimen, such as feces, saliva, urine, blood, and tissue. This molecular diagnostic is based on seeing targeted portions of microbial genetic material, DNA or RNA. It is utilized by the healthcare sector to detect emergency usage authorization to diagnose diseases. Point-of-care (POC) molecular diagnostic is used to detection of disease antigens or antibodies in human samples, such as mononucleosis, influenza, and group A streptococcus (GAS).
View More Reports Related To The Point-Of-Care Molecular Diagnostics Market –
Point-Of-Care Diagnostics Devices And Equipment Global Market Report 2023
Molecular Diagnostics Devices And Equipment Global Market Report 2023
Oncology Molecular Diagnostics Global Market Report 2023
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: